There is no generic version of Mounjaro (tirzepatide) available, and one is unlikely to reach the market for several years. Mounjaro is made by Eli Lilly, which holds patent protections on the drug. With a list price of $1,112.16 per month, the lack of a generic leaves many people looking for alternatives to bring the cost down.
Why a Generic Doesn’t Exist Yet
Mounjaro was approved by the FDA in 2022, and Eli Lilly’s patents on tirzepatide extend well into the 2030s. Until those patents expire or are successfully challenged, no other manufacturer can produce a true generic version. This is standard for newer brand-name drugs, which typically enjoy years of market exclusivity before generics can enter.
There’s also a structural reason a traditional generic may never exist for this drug. Tirzepatide is a large, complex peptide molecule, not a simple chemical compound like the active ingredient in a typical pill. For drugs like these, the equivalent of a generic is called a “biosimilar,” a near-copy that must go through its own clinical testing to prove it works the same way. Biosimilars take longer and cost more to develop than standard generics, which means even after patent expiration, it could take additional years before a lower-cost biosimilar version reaches pharmacies.
Zepbound: Same Drug, Different Label
While there’s no generic, there is another FDA-approved product that contains the exact same active ingredient at the exact same strengths. Zepbound, also made by Eli Lilly, is tirzepatide approved specifically for chronic weight management and obstructive sleep apnea. Mounjaro is approved for type 2 diabetes. Both come in identical dose strengths ranging from 2.5 mg to 15 mg.
This distinction matters because your insurance plan may cover one but not the other depending on your diagnosis. They are not interchangeable at the pharmacy level since they carry different brand names and approved uses, but the medication inside is the same.
Compounded Tirzepatide: Lower Cost, Higher Risk
During periods when Mounjaro was in shortage, some compounding pharmacies began making their own versions of tirzepatide. These compounded products are significantly cheaper, which has made them popular. But they come with real safety concerns that are worth understanding before pursuing this route.
Compounded drugs are not reviewed by the FDA for safety, effectiveness, or quality before they are sold. As of July 31, 2025, the FDA had received 545 reports of adverse events associated with compounded tirzepatide. Some of those reports involved doses beyond what appears on the FDA-approved label, meaning patients were prescribed higher single doses, more frequent injections, or faster dose increases than the approved version calls for.
The FDA has also identified outright fraud in this space. Some products labeled as compounded tirzepatide listed pharmacies on their labels that either don’t exist or didn’t actually make the product. At least one adverse event was linked to a product falsely labeled as coming from a specific pharmacy. The agency has also warned companies selling products containing tirzepatide labeled “for research purposes” or “not for human consumption” that were clearly being sold to people with dosing instructions included.
To limit the supply of questionable ingredients entering the country, the FDA established an import alert specifically targeting GLP-1 active pharmaceutical ingredients with potential quality concerns. If you’re considering a compounded version, the safest path is through a state-licensed compounding pharmacy with a valid prescription from your doctor, not through an online retailer or direct-to-consumer website selling vials without a prescription.
Ways to Reduce the Cost of Brand-Name Mounjaro
Eli Lilly offers a savings card program that can significantly lower your out-of-pocket cost, though eligibility depends on your insurance situation. If you have commercial insurance that covers Mounjaro, the savings card can bring your cost down to as little as $25 per month. The card covers up to $150 in savings per one-month fill, with a maximum annual benefit of $1,950. It can be used for up to 13 fills per calendar year.
If you have commercial insurance that does not cover Mounjaro, the savings card still helps, reducing the price to as low as $499 per month. In this case, the card provides up to $647 in monthly savings and up to $8,411 annually. The current card expires at the end of 2026.
There are important exclusions. You cannot use the savings card if you’re enrolled in Medicare, Medicaid, TRICARE, VA benefits, or any other government-funded healthcare program. You also must be 18 or older, live in the United States or Puerto Rico, and have a prescription for an FDA-approved use. People whose insurance plans require them to go through an alternate funding program as a condition of coverage are also ineligible.
What to Expect Going Forward
For now, your options are the brand-name product (Mounjaro or Zepbound depending on your diagnosis), compounded versions with the caveats described above, or waiting for biosimilar competition that likely won’t arrive until the mid-to-late 2030s at the earliest. The savings card program is the most straightforward way to lower costs if you have commercial insurance. If you don’t have insurance coverage at all, the $1,112.16 monthly list price is the starting point, with the savings card potentially bringing that closer to $500.